HIGHLIGHTS
SUMMARY
The total cost of LB was estimated through an incidencebased costing approach for patients with (i) an EM (including multiple EM) or (ii) disseminated/late LB, including patients who later developed PTLDS. In the current analysis, costs occurring until six months after treatment were included for EM patients and disseminated/late LB patients and costs occurring until 12 months for patients with PTLDS. For hospitalized patients in the cohort study, costs occurring during these hospitalizations, e_g, part of treatment, laboratory testing, were removed as these are calculated based on separate data (see further). While . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.